Evidence is presented for the existence of a novel remodeling-by-deletion mechanism that alters the ®ne structure of c-myc-deregulating chromosomal translocations in t(12;15)-positive BALB/c plasmacytomas. DNA sequence analysis of the t(12;15) in ®ve primary tumors revealed the co-existence of precursor cells harboring genetic recombinations between the immunoglobulin heavy-chain m locus (Ighm) and c-myc with clonally related progenitors containing rearrangements between the immunoglobulin heavy-chain a locus (Igha) and cmyc. Clonal relatedness was based upon unique junction fragments between the switch region of Ighm and c-myc. Sm/c-myc junctions are thus useful clonotypic markers for monitoring the conversion of Ighm/c-myc-positive tumor precursor clones into Igha/c-myc-positive plasmacytomas. Aberrant isotype switch recombination appears to be the most likely mechanism eecting this conversion event (other possibilities are discussed) which may help to explain the preferred usage of the Igha locus in recombinations with c-myc in t(12;15)-positive plasma cell tumors in BALB/c mice.
Introduction
Virtually all plasmacytomas developing in genetically susceptible inbred BALB/cAnPt mice (Potter and Wax, 1983) or hypersusceptible congenic BALB/cAnPt.DBA/ 2N-Idh1-Pep3 mice are characterized by a disruption in or near the proto-oncogene cmyc which leads to deregulated, constitutive expression of c-myc transcript and protein on the aected allele. In pristane (2,6,10,14-tetramethylpentadecane)-induced BALB/c plasmacytomas, c-myc-deregulating genetic recombinations usually take the form of reciprocal chromosomal translocations t(12;15). This translocation juxtaposes c-myc, residing on band D2/3 of chr. 15, to genes of the immunoglobulin heavy-chain locus (Igh), located on band F1 of chr. 12, and results in an enlarged chromosome (chr.) 12, designated chr. 12 + , and a reduced chr. 15, denoted chr. 15
7 (Potter and Wiener, 1992) . The presence of the aberrant derivative chromosomes can only be proven by cytogenetic analysis using conventional (Wiener et al., 1984) and/ or molecular (Liyanage et al., 1996) tools. However, we have recently developed PCR methods to faithfully detect the t(12;15) in plasmacytoma cells and their precursors, which enables us to overcome some of the technical limitations of cytogenetics with respect to number, location, and types of B cells that can be scrutinized for translocations (Janz et al., 1993; MuÈ ller et al., 1994 MuÈ ller et al., , 1995 .
At the molecular level, the t(12;15) is characterized by juxtaposition of the 5' region of c-myc, stretching from about 1 kbp upstream of the non-coding exon 1 to the 3' end of intron 1, to an Igh switch region (S). Of importance, the seven S regions (Sm, Sg3, Sg2a, Sg2b, Sg1, Se, Sa) and the CS region of the Ighd locus do not participate equally in recombinations with cmyc; instead, there is a strong bias toward Sa which is utilized in *80% of the t(12;15)-positive plasmacytomas so far studied (Potter and Wiener, 1992) . The reason for the preferred usage of Sa is currently unclear, but we propose that the`remodeling' mechanism that was detected in this study in ®ve primary plasmacytomas contributes to that pereference. In these tumors, related clones with recombinations between Ighm and c-myc were found to co-exist with clones harboring exchanges between Igha and cmyc. Clonal relationship was established by ®ne structural analysis of recombinational fragments between Igh genes and c-myc, revealing clonotypic Sm/c-myc junctions that were detected in both Ighm/cmyc and Igha/c-myc fragments.
We suggest that abnormal class switching is instrumental in a remodeling-by-deletion process that transforms Ighm/c-myc precursor lesions into Igha/cmyc product lesions. Remodeling results in repositioning of c-myc over a distance of about 170 kbp from the most upstream gene of the Igh gene cluster, Ighm, to the most downstream one, Igha, and places the recombined c-myc gene in close proximity to the enhancer elements that are positioned 3' of Ca. The relocation of c-myc may be of biological importance by eecting the transcriptional upregulation of the gene. We propose to consider deletional remodeling of cmyc-degregulating translocations as a novel tumor progression mechanism in mouse plasmacytoma development.
Results

Genetic recombinations between Ighm and c-myc in primary plasmcytomas
Two major problems that are caused by intrinsic properties of the Sm region were encountered in initial attempts to PCR amplify junctional fragments between Ighm and c-myc. The ®rst problem was posed by the highly repetitive structure of Sm that consists mainly of tandem pentameric repeats (GAGCT and GGGGT), and the second one was produced by the subtantial length of the Sm region, amounting to approximately 3.5 kbp in BALB/c mice. Both obstacles were overcome by designing long range and high ®delity PCR techniques that utilize unique primer annealing sites within the non-repetitive¯anking regions of Sm. Such PCR methods were developed and employed here to test the hypothesis that BALB/c plasmacytomas, which are characterized by the typical Igha/c-myc rearrangement on chr. 12 + , may have evolved from precursor cells in which c-myc was joined with Ighm on chr. 12 + . Thirty-®ve plasmacytomas were originally included in this study, and junctional fragments between c-myc and Ighm (originating in the ®rst exon of the Ighm locus, Cm1) were detected in ®ve plasmacytomas (Table 1) . This ®nding suggests that translocations t(12;15) resulting in Ighm/c-myc recombinations may not be as rare in BALB/c plasmacytomagenesis as previously thought . Four out of ®ve Ighm/cmyc-positive plasmacytomas were found to be advanced tumors, as indicated by detailed histologic analysis of the tissue in®ltration pattern by malignant plasma cells. PCT 4132 was the exceptional example which was obtained at an early stage of tumor development with very little in®ltration by plasmacytoma cells (data not shown).
Fine structure of Ighm/c-myc recombinations
Some features of the observed Ighm/c-myc exchanges warrant particular consideration. First, the break in cmyc on chr. 12 + occurred upstream of exon 1 in four out of ®ve tumors (Figure 1 ), placing these tumors in the unusual class II category of plasmacytomas according to Cory (Cory, 1986) . Second, in all ®ve tumors, reciprocal products of translocation were found, establishing the prerequisite to analyse the precision of the genetic exchange by DNA sequencing. The analysis revealed a remarkable accuracy of recombination in c-myc in four tumors, in which no more than 9 bp were lost during the break and rejoining event: 5 bp in TEPC 1194, 7 bp in PCRT 4127, 9 bp in Table 1 ). Annealing sites for PCR primer pairs that were used to amplify junctional fragments between Ighm and c-myc are depicted by horizontal arrows that are labeled. Primer pairs myc5'1 and m5'1 were employed to generate chr. 12 + -typical fragments and primer pairs myc3'1 and m3'1 were utilized to detect recombinations on chr. 15 7 TEPC 3609, and no deletion at all in TEPC 3610 (Figure 1 ). In the ®fth tumor, PCT 4132, the determination remained inconclusive, which was caused by the presence of two distinct chr. 15
7
-typical Ighm/c-myc junctional fragments that could potentially correspond to the chr. 12 + -typical fragment. This situation precludes the unambiguous assignment of reciprocal products of translocation and, thus, the detection of any deletions that might have occurred in c-myc. However, we note that the deletion in c-myc in PCT 4132 would also be quite small, amounting to 32 bp, if the chr. 15
-typical Ighm/c-myc junction fragment with the most downstream break in c-myc (shown in line 7 in Table 1 ) was arbitrarily matched with the chr. 12 + -typical fragment shown in Figure 4 . Third, Ighm/c-myc-positive plasmacytomas are invariably accompanied by large deletions in Sm. In four out of ®ve plasmacytomas, in which the break in the Ighm locus occurred in Sm (Figure 1 ), 3 kbp, 1.5 kbp and 1.0 kbp long internal deletions (in PCT 4127, TEPC 3609 and TEPC 3610, respectively) and loss of the entire 2.8 kbp upstream part of Sm (in PCT 4132) were found. The ®fth tumor, TEPC 1194, was peculiar, since recombination in Ighm occurred upstream of Sm (in its near 5'¯ank) and took place as a nearly precise reciprocal exchange that resulted in a loss of just 5 bp in the 5'-Sm region. Nevertheless, Sm residing on chr. 12 + had also undergone a large, 2.6 kbp long internal deletion (Figure 2) , as in the other four plasmacytomas.
Ighm/c-myc recombinations as molecular precursors for Igha/c-myc recombinations in primary plasmacytomas
The most remarkable feature of the plasmacytomatypical Ighm/c-myc recombinations was noted when chr. 12 + -typical breakpoint regions between Ighm and c-myc were compared with chr. 12 + -typical Igha/c-myc exchanges that were co-detected in identical samples of tumor DNA. That comparison uncovered precursor and product relationship between both types of Igh/cmyc exchanges and established Ighm/c-myc junctions as molecular precursors for Igha/c-myc recombinations (Figures 2 ± 6). Interestingly, the Ighm/c-myc-positive Bcell clones appeared to be more abundant than the Igha/ c-myc-positive B-cell clones in four out of ®ve plasmacytomas, TEPCs 1194, 3609 and 3610 and PCT 4127, in which recombinational fragments between Ighm and c-myc were detected after one round of PCR but recombinational fragment between Igha and c-myc only after two rounds of PCR (see Figures 2, 3, 5 and 6 for depicted PCR primer pairs). This is, in our experience, a reasonable indicator of clonal abundance. Nevertheless, we attempted to con®rm this result by Southern blotting with probes hybridizing to appropriate indicator regions of Ighm, Igha and c-myc. Unfortunately, most of the recombinational fragments of c-myc were too scarce to be detected by Southern analysis, which only revealed the chr. 12 + -typical Ighm/c-myc fragments in TEPC 1194 and PCT 4127 (result not shown) after digestion with EcoRI.
Clonal diversity in primary plasmacytomas
Numerous PCR experiments with dierent combinations of primer pairs were carried out to verify the presence of remodeled clones with genetic exchanges Figure 2 Remodeling of Ighm/c-myc recombination on chr. 12 + in primary plasmacytoma, TEPC 1194. Shown at the top is a schema of the structure of the initial balanced exchange between Ighm and c-myc which joined the near 5'¯ank of c-myc with the near upstream region of Sm, 5'-Sm. The two genes were recombined head to head (5' to 5') on chr. 12 + and tail to tail (3' to 3') on chr. , which are denoted by ®lled circles at the right end of the map, by a very large distance that is indicated by an oblique double line to the left of the acromere. PCR fragments that were used to dierentiate between Ighm/c-myc and Igha/c-myc recombinations and to determine the ®ne structure of the t(12;15) by DNA sequencing are indicated by horizontal bars below the gene maps. PCR primer pairs used to generate individual fragments are shown by arrowheads below ends of bars. A single pair of arrowheads indicates that the fragment was abundant and detectable after a single round of PCR. Two pairs of arrowheads refer to two rounds of PCR with nested primer pairs that were required to detect a less abundant fragment. A 1375 bp long chr. , have been determined and deposited in Genbank under accession numbers U45428 and U45429, respectively. Note that the Sm region harbors two internal deletions that are indicated by ®lled triangles pointing up. The structural schema of the topmost, remodeled Igha/c-myc recombinational fragment on chr. 12 + shows that Sm was joined to Sa in a tail-to-head recombination which generated a composite Sm/Sa region. The Igha/c-myc recombination breaksite and¯anking regions of that fragment were determined with a PCR product, shown as a grey bar below the map labeled as #1, that was generated with the primer pairs myc5'1a/b and a5'1a/b. Using the same primer pairs, ®ve additional Igha/c-myc fragments were found and labeled as #2 to #6. These fragments are characterized by unique junctions between switch regions: Sm, or 5'-Sm in the bottom most fragment, and Sa. However, the initial junction site between 5'-Sm and c-myc has been preserved during secondary genetic recombination between switch regions and is therefore common to all six Igha/c-myc junctional fragments. This is indicated by the DNA sequence of the clonotypic breakpoint region between 5'-Sm and c-myc of which 60 bp are given below the bottom most PCR fragment. 30 bp of cmyc and Igh are shown in lower case letters and italics, respectively, and the breaksite is denoted by a gap between c-myc and Ighm or Igha. During repeat analyses, additional B-cell clones harboring t(12;15)-typical Igh/c-myc recombinations became apparent in all ®ve`remodeled' tumor samples. Most of the PCR fragments indicating these clones were of lesser abundance, since they required at least two rounds of PCR for detection and usually several experiments to recon®rm their presence. However, two plasmacytomas, TEPC 1194 and PCT 4132, showed a remarkable number of accessory clones and were chosen for a detailed evaluation of clonal diversity. In PCT 4132, six clonotypic Igh/c-myc recombinational products (lines 6 ± 11 in Table 1) were detected in addition to the two + -typical structure of the initial recombination between Sm and c-myc. A structural schema of the secondary, remodeled Igha/c-myc recombination is illustrated below. Note that two recombination events joined Sm, Sg2b and Sa in a compound switch region that is indicative of sequential deletion events. A characteristic base substitution mutation in cmyc that was detected in both the precursor and the remodeled fragment is shown by the capital G in the sequence at the bottom. A 240 bp long DNA sequence which includes the breakpoints between c-myc, Sm, Sg2b and Sa is depicted by an open box in the Igha/c-myc indicator fragment and has been deposited in GenBank under accession number U60446. Compare with Figure  2 for further explanations of symbols used Figure 5 Remodeling of Ighm/c-myc recombination on chr. 12 + in primary plasmacytoma, TEPC 3609. Shown at the top is a structural schema of the reciprocal products of the initial translocation t(12;15) joining the near 5'¯ank of c-myc with Sm. Shown at the bottom is a schema of the structure of the secondary Igha/c-myc recombination. Two unique base substitution mutation in c-myc that was detected in both the precursor and the remodeled fragment are indicated by the capital letters in the sequence at the bottom. See Figure 2 for detailed description of symbols Figure 6 Remodeling of Ighm/c-myc recombination on chr. 12 + in primary plasmacytoma, TEPC 3610. Shown at the top is a structural schema of the reciprocal products of the initial translocation t(12;15). On chr. 12 + , the near 5'¯ank of c-myc is joined with Sm. On chr. 15 7 , however, the combined Sm/5'-Sm region adjacent to the translocation breakpoint (depicted by a grey rectangle) has undergone inversion, resulting in the juxtaposition of 5'-Sm to c-myc in a head-to-tail recombination (5' to 3') that is unusual for a chr. 15 7 -typical junctional fragment. In addition, the inverted Sm region contains an internal rearrangement that is denoted by a ®lled triangle pointing up. Shown at the bottom is a schema of the structure of the secondary Igha/c-myc recombination. 30 bp of c-myc and Igh are shown in lower case letters and italics, respectively, and the breaksite is denoted by a gap. See Figure 2 for detailed description of symbols junctional fragments that were related by remodeling (line 5 in Table 1 ). Five of the additional recombination fragments were indicative of rearrangements on chr. 15 7 and one of a recombination event on chr. 12 + . This ®nding, in conjunction with the histologic data in PCT 4132 mentioned above, suggests that this tumor represents an incipient plasmacytoma that was analysed at an early stage of tumor progression in which clonal diversity was abundant. Moreover, it lends support to previous data on the co-evolution of multiple independent B-cell clones during plasmacytomagenesis (Morse et al., 1976; Potter et al., 1994; MuÈ ller et al., 1995) . Clonal variety in TEPC 1194 was re¯ected by the presence of a total of six distinct chr. 12 + -typical Igha/c-myc fragments that were reproducibly detected in the tumor sample. However, it remains unclear whether these fragments indicate the presence of independent clones of aberrant Igha/c-myc-positive B cells that originated from a common Ighm/c-mycpositive precursor cell. Alternatively, the PCR fragments may point to the existence of closely related subclones of B cells that have been derived from a common Igha/c-myc-positive precursor clone. The uncertainty is caused by the shared 5'-Sm/c-myc junction site that was observed in all six Igha/c-myc fragments, illustrating a situation in which independent remodeling events can not be distinguished from secondary deletions in a common Igha/c-myc precursor breakpoint region (see Figure 2 for details).
Discussion
The basic ®nding described in this paper is the identi®cation of ®ve plasmacytomas, TEPCs 1194, 3609 and 3610 and PCTs 4127 and 4132, in which primary clones of cells with Ighm/c-myc recombinations were found to be precursors of tumor cell clones with Igha/c-myc recombinations. The possibility that such a precursor and progenitor relationship indeed existed was already suggested by earlier results, including (i) the presence of numerous chr. 12 + -typical Sm/c-myc junctions in B cells that were detected with degenerate PCR primers possessing multiple annealing sites in Sm and Sa (MuÈ ller et al., 1997), (ii) the occurrence of composite Sm/Sa regions in primary t(12;15)-positive plasmacytomas with an Igha/c-myc exchange on chr. 12 + (MuÈ ller et al., 1995) , and (iii) the ®ne structure of the genetic recombination between Ighm and c-myc in the unusual BALB/c plasmacytoma, TEPC 1194 Kovalchuk et al., 1996) . Direct evidence for clonal relatedness between Ighm/c-myc-positive and Igha/c-myc-positive cells, however, is presented in this study on primary plasmacytomas, in which identical clonotypic Sm/c-myc junctions were co-detected in both Ighm/c-myc and Igha/c-myc breakpoint regions. Additional support for the presence of precursor and product relationship was obtained in two tumors, PCT 4132 and TEPC 3609, wherein the tumor-typical Sm/c-myc junctions were further de®ned by speci®c base substitution mutations in c-myc. Thus, the clonotypic Sm/c-myc exchanges proved to be useful as molecular ®ngerprints to trace clonal descendence during plasmacytoma development. The most plausible explanation for our data is that Sm/c-myc rearrangements were established during the genetic exchange between Ighm and c-myc as the primary event and, subsequently, preserved as part of composite Sm/ Sa regions in Igha/c-myc breakpoint regions that originated in a secondary recombination event.
We propose that primary Ighm/c-myc recombinations are`remodeled' into secondary Igha/c-myc recombinations by a mechanism utilizing aberrant isotype switching according to the looping-out-anddeletion model. Our proposal is based on the the observations that (i) recombination breakpoints in participating switch regions (Sm, Sg2b and Sa) occurred in repetitive regions which is typical for normal switch recombination, (ii) the composition of the compound switch regions, Sm/Sa in TEPCs 1194, 3609, 3610 and PCT 4127 or Sm/Sg2b/Sa in PCT 4132, is indistinguishable from structures resulting from normal switching, and (iii) switching to Ca in PCT 4132 involved an intermediate switch acceptor region, Sg2b, in a sequential class switch recombination event known to take place during isotype switching in normal B cells (Coman et al., 1993; Harriman et al., 1993) . Precedence for illegitimate genetic recombinations in B cells mediated by aberrant isotype switching has been reported by other investigators who showed that abnormal class switching can apparently eect both inter-and intrachromosomal genetic exchanges. A well-documented example of transchromosomal switch recombination is provided by the reciprocal chromosomal translocation t(5;12) that results from the genetic recombination of a human Cm transgene, residing on mouse chr. 5, with one of the mouse Igh genes on chr. 12 (Gerstein et al., 1990) . Additional examples of rearrangements suggestive of having occurred in trans have been described with the integration of a long interspersed nuclear element (LINE) next to the Se region in a rat plasmacytoma (Pear et al., 1988) and the interruption of the Sg2a region in a mouse plasmacytoma by an early transposon-like element, E.Tn (Elenich and Dunnick, 1991) . Examples in which switch recombinase may have been instrumental in generating inappropriate intrachromosomal rearrangements include the recombination of a LINE-1 element with the expressed Igh cluster in a subline of mouse plasmacytoma MPC 11 (Bard and Birshtein, 1995) and the ®ndings of this study.
We can not prove at present that recombinations between Ighm and c-myc are modi®ed by aberrant isotype switching and need to consider, therefore, alternative mechanisms. We realize, for example, that DNA sequence analysis of composite switch regions does not allow to distinguish between abnormal switch recombination and illegitimate recombination between switch regions (Dunnick et al., 1993) , with the latter taking place as a simple repair-and-rejoining event of DNA double strand breaks in switch regions or as unequal sister chromatid exchange between switch regions. Additionally, mechanisms which are more complex may be invoked to explain remodeling, such as (i) intrachromosomal recombinations subsequent to ampli®cation events on chr. 12 + involving the combined Igh/c-myc locus, (ii) unequal crossing over between chr. 12 + and its normal homolog, chr. 12, and (iii) duplications of chr. 12 + followed by transchromosomal rearrangements between the aberrant chromosomes. An interchromosomal mechanism in particular may be less remote than one might assume, since plasmacytomas are almost invariably (hypo)tetraploid tumors that usually have two copies of chrs. 12 and 12 + available for transchromosomal exchanges.
We do not know when during malignant B-cell development recombination between Ighm and c-myc occurs, nor do we know when remodeling of c-myc rearrangements by abnormal class switching takes place. One possibility we consider envisions the Ighm/ c-myc exchange in a mature, class switch competent Bcell that has encountered antigen and other appropriate signals and prepares itself for isotype switching. In this situation, the initial lesion that provokes illegitimate recombination between Ighm and c-myc may be a DNA double-strand break in Sm due to internal rearrangements of Sm, mostly deletions and occasionally inversions, known to occur prior to class switching (Radbruch et al., 1986; Dunnick et al., 1989) . The interruption of Sm may lead to Ighm/c-myc recombination and chromosomal translocation t(12;15) on the non-productive Igh allele, followed by deletional remodeling' of the t(12;15) by aberrant class switch recombination and normal class switching on the productive Igh allele (see Figure 7 for more details). The exact sequence of these events is currently unclear, but the ®nal result of the processes illustrated in Figure  7 appears to be in agreement with one of the general rules of class switching, namely that both nonproductive and productive alleles frequently rearrange to the same C H gene (Winter et al., 1987) . The proposed model also agrees with the empirical ®nding in BALB/c plasmacytomas that most tumors have switched both the heavy-chain encoding and the translocated Igh allele to Ca.
The biological signi®cance of the`remodeling' of cmyc-deregulating chromosomal translocations is not known, but we speculate that it is related to an upregulation of c-myc message which may be accomplished by relocating c-myc to the Igha locus. Recombination of c-myc with Sm removes all known upstream Igh enhancer and promoter elements from chr. 12 + , including the intronic Igh enhancer, regulatory regions 3' of the intronic Igh enhancer (Sigurdardottir et al., 1995) , the DQ52 enhancer/ promoter (Kottmann et al., 1994) and additional promoters that are associated with D elements and V H genes. Thus, no positive regulator of c-myc expression appears to be available in the 5' portion of the heavy-chain gene complex after genetic exchange with Ighm. In this situation, transcription of c-myc can only be accomplished by enhancer elements possibly present in the 3'¯ank of c-myc or by the enhancers Figure 7 Deletional remodeling of the t(12;15) during plasmacytoma development in BALB/c mice: a working model. Shown in the left upper corner is a mature IgM + B cell that is postulated to be the plasmacytoma precursor cell. The precursor B cell is anticipated to have undergone VDJ rearrangement on one chr. 12 and illegitimate recombination between Ighm and c-myc on the other chr. 12. Productive VDJ recombination on the ®rst chr. 12 resulted in the production of the m heavy-chain and, subsequent to pairing with a k or l light-chain, in the surface expression of IgM. Interruption of the Ighm locus on the second chr. 12 led to the transchromosomal exchange with the c-myc gene residing on chr. 15. The resulting translocation t(12;15), indicated by an arrow pointing up, produced the hybrid chr. t(12;15) which is often referred to as chr. 12 + since the chimeric chromosome becomes visible in the cytogenetic analysis of plasmacytomas as a distinctively enlarged chr. 12. The biological properties of the t(12;15)-positive precursor B cell are unknown, but it is not unlikely that this cell participates in many selection, proliferation, and dierentiation processes that are typical for normal B cells. The order and location of the eight loci of the mouse Ig heavychain gene complex on chr. 12 is included in the schemata that are shown to the right of the precursor cell. C H genes are depicted by open rectangles that are labeled. Preceding switch regions are indicated by black dots, except for Ighd which has no switch region proper. The two major enhancers that regulate heavy-chain transcription are shown as diamonds: the intronic enhancer positioned upstream of Sm and the enhancers of the locus control region that is located 3' of Ca. The coding portion of the c-myc gene is symbolized by an open labeled rectangle. Illustrated in the lower left corner is a plasmacytoma cell that typically, i.e. in about 65% of tumors, produces and secretes IgA. The tumor cell has undergone normal class switching to Ca on chr. 12 and abnormal class switching to Ca on chr. 12 + . Both switch events eected the loss of all Igh genes that are located upstream of Ca, which is the most distal gene in the Igh gene cluster. Normal isotype switching to Ca is the precondition for the expression of the a heavy-chain postulated to maintain the VDJ rearrangement and thus the immunologic speci®city of the m heavy-chain expressed by the precursor B cell. The aberrant isotype switch event on chr. 12 + resulted in the`remodeling' of the ®ne structure of the t(12;15) by a large deletion which converted the original Ighm/c-myc exchange into an Igha/c-myc exchange (indicated by an arrow pointing up). This Igha/c-myc exchange on chr. 12 + is characteristic for established t(12;15)-positive plasmacytomas in which it occurs with a frequency of about 80%. Note that remodeling results in the approximation of c-myc to the 3'-Ca enhancer region which may be of some importance for the transcriptional upregulation of the translocated c-myc gene in the plasmacytoma cells. It is important to emphasize that the proposed model on the evolution of the Ighm/c-myc-positive precursor into the Igha/c-myc-positive tumor cell does not predict whether normal class switching on chr. 12 and abnormal switching on chr. 12 + occur simultaneously or as two independent recombination events separated in time. Therefore, the existence of transitional, intermediate cell types needs to be considered in which delayed recombinations, either on chr. 12 or chr. 12 + , may take place. Two extreme intermediates are depicted in the center: the isotype non-switched IgM + B cell harboring thè remodeled' Igha/c-myc exchange and the isotype switched IgA + B cell containing the primary Ighm/c-myc exchange. Many additional intermediate cell types may be generated during plasmacytomagenesis if one allows for the coexistence of various combinations of recombinational structures on chr. 12 and 12 + involving Ighd, Ighg, and Ighe in addition to Ighm and Igha. Furthermore, the model outlined here implies that dierent B-cell intermediates may have progressed to a dierent degree along the plasmacytic dierentiation pathway. For example, the IgA + B cell with the Ighm/c-myc exchange may already have completed plasmacytic dierentiation, while the IgM + B cell with the Igha/cmyc exchange may still remain at the development stage of a mature lymphocyte. Ongoing clonal diversi®cation generating a continuum of aberrant, dierentiating B cells harboring the t(12;15) at various stages of`remodeling' may thus characterize plasmacytoma development in BALB/c mice that are located 3' of Ca (Pettersson et al., 1990; Dariavach et al., 1991; Matthias and Baltimore, 1993; Madisen and Groudine, 1994; Michaelson et al., 1995) . However, 3'-c-myc enhancers have not been identi®ed thus far, and the two candidate enhancer elements that were recently found in a molecular analysis of the 30 kbp downstream region of the human c-myc gene (Mautner et al., 1995) have been shown in subsequent studies to be insucient to upregulate c-myc expression in vivo (Mautner et al., 1996) . On the other hand, the 3'-Ca region contains several strong enhancers which have already been shown to eciently activate c-myc expression (Madisen and Groudine, 1994) , suggesting that the 3'-Ca enhancers may be the critical control elements for the deregulation of c-myc in plasmacytomas (Arulampalam et al., 1995) . The regulation of the 3'-Ca enhancers is not yet understood, but it has already become clear that the enhancers are temporally (co)regulated and that some enhancer functions become fully active only in late B cells such as plasma cells (Michaelson et al., 1996; Singh and Birshtein, 1996) . Thus, the dierentiation-dependent activity of the 3'-Ca enhancers as well as the close approximation of c-myc to these enhancers by the remodeling-bydeletion process outlined here may cooperate to secure the constitutive deregulation of c-myc transcription which is a hallmark of BALB/c plasmacytomas. This hypothesis needs to be formally proven, however, for example by transcriptional studies that are aimed at comparing the levels of normal and aberrant c-myc message at dierent stages of B-cell dierentiation as well as after recombination of c-myc with dierent Igh loci.
The proposed`remodeling' model needs to be reconciled with the existence of plasmacytomas containing recombinations between Ighm and c-myc on chr. 12 + . These tumors were obviously able to complete plasmacytoma development without`remodeling' the t(12;15) and raise questions, therefore, as to how requisite remodeling really is for plasmacytomagenesis. Relevant examples include the plasma cell tumors ABPC 17 (Corcoran et al., 1985) , DCPC 21 (Ohno et al., 1989 (Ohno et al., , 1991 , ABPC 45 (Fahrlander et al., 1985 ), PC 7183 (VanNess et al., 1983 and MPC 11 (Greenberg et al., 1982) . However, closer examination of the Ighm/c-myc exchanges in these plasmacytomas reveals their invariably exceptional nature that is characterized by unique and, in some cases, complex genetic rearrangements which involved (i) the insertion of the intronic Ig heavy-chain enhancer in the 5' regulatory region of c-myc (Corcoran et al., 1985; Ohno et al., 1989 Ohno et al., , 1991 , (ii) the juxtaposition of c-myc to an inverted stretch of Sm (Greenberg et al., 1982) , (iii) the recombination of c-myc with a composite and inverted Sm/Sa region (Fahrlander et al., 1985) or (iv) the formation of a tripartite recombination structure including c-myc, Sm and Igk that was built from three dierent chromosomes (VanNess et al., 1983) . Thus, the diversity of this tumor sample and the lack of information about possible additional rearrangements outside the immediate translocation breakpoint region (e.g., large deletions in the Igh gene cluster) makes it dicult at present to recognize the common denominator that may have permitted the Ighm/c-myc-positive progenitor cells to complete plasmacytoma development. In addition, it is conceivable that exchanges between Ighm and c-myc are in principal permissive for the development of a minority (subgroup?) of plasmacytomas, suggesting that the`remodeling pathway' of plasmacytomagenesis described here may be commonly used in a particular subset of plasmacytomas but not universally utilized for the development of all t(12;15)-positive plasmacytomas.
Along these lines, we note that four out of ®ve primary tumors that were included in this study belong to the so-called class II category of plasmacytomas (Cory, 1986) . In these tumors the breakpoint in c-myc occurred 5' of exon 1. The upstream breaksite location resulted in the preservation of the main c-myc promoters, P1 and P2, on chr. 12 + , since these promoters are positioned at the beginning of exon 1. Retaining the P1 and P2 sites on the c-myc-deregulating chr. 12 + may be of functional signi®cance, as noted earlier by other investigators , because a model can be evoked which predicts that the presence of the P1 and P2 promoters may somehow facilitate the transcription of c-myc in the context of an Ighm/c-myc exchange. Even though it is not known whether transcription from P1 and P2 may be activated without remote support from the 3'-Ca enhancers, which in this situation are about 170 kbp away from the deregulated c-myc gene, or with their support, the model postulates that the Ighm/c-myc-positive B cells maintaining the P1/P2 promoters on chr. 12 + may have a growth and/or survival advantage. The model further implies that transcriptional activation of c-myc is less likely to occur after class I translocation in an Ighm/cmyc-positive B cell, since the translocation breakpoint in intron 1 of c-myc will result in the removal of P1 and P2 from the Myc protein encoding exons 2 and 3. Thus, if B cells harboring an exchange between Ighm and cmyc do require the 3'-Ca enhancers for c-myc expression, the establishment of the long-range interaction between c-myc and the enhancers may depend on the promoter availability in c-myc and may favor class II over class I translocations. This hypothesis needs formal support, but it provides a concept in which the location of the initial breaksite in c-myc acts as a discriminator for selecting appropriate progenitor cells from the pool of t(12;15)-positive B cells for continuing oncogenic evolution.
On a conjectural note, remodeling of chromosomal translocations, as described here for BALB/c plasmacytomas, may not be con®ned to the mouse, but may also occur in humans; speci®cally in B-cell lymphomas harboring a translocated chr. 14q32. There is some circumstantial evidence to suggest that the ®ne structure of two types of reciprocal chromosomal translocations involving chr. 14q32 may be modi®ed by a remodeling mechanism: the t(14;18) that is typical for follicular lymphomas (Zelenetz et al., 1993) and the t(14;19) that can be observed in a subtype of chronic lymphocytic leukemia (Crossen et al., 1993) . What is more, sporadic Burkitt's lymphoma may also be a candidate for remodeling on chr. 14q32, even though there is no direct evidence available at the moment to support this proposition. However, some parallels between BALB/c plasmacytoma and Burkitt's lymphoma are tantalizing: First, in Burkitt's lymphoma, Igh genes, usually Ighm, are recombined with c-myc on chr. 14q32 in a way that is analogous to chr. 12 + in BALB/c plasmacytomas. Second, translocation results, as in mouse plasmacytoma, in deregulation of c-myc. Third, recent studies on the ®ne structrue of the Igh/c-myc recombination on chr. 14q32 revealed the frequent involvement of Ighg and Igha in addition to the most commonly used Ighm locus (MuÈ ller et al., 1995; Akasaka et al., 1997) . Therefore, some of the Burkitt's lymphomas with Igha/c-myc or Ighg/c-myc recombinations may have originated from precursor cells with Ighm/c-myc rearrangements.
Materials and methods
Induction and diagnosis of plasmacytoma
Plasmacytomas were induced by injection of pristane (2,6,10,14-tetramethylpentadecane, Aldrich, Milwaukee, WI) into the peritoneal cavity of mice that were bred and maintained at our conventional mouse facility (PerImmune, Rockville, MD) under NCI contract N01-BC-21085. Tetramethylpentadecane-induced plasmacytomas (TEPCs) 1194, 3609 and 3610 originated in inbred BALB/cAnPt mice. Pristane-induced plasmacytomas (PCTs) 4127 and 4132 were induced in congenic BALB/ c.DBA.2N-Idh1-Pep3 mice. Incipient plasmacytomas were detected using cytofuge specimens of ascitic cells that were obtained from mice by peritoneal puncture, stained with Wright-Giemsa and found to contain ten or more hyperchromatic, atypical plasma cells. After cytologic evidence for plasmacytoma had been established, the mice were sacri®ced and a variety of tissues including tumor nodules and adjacent oil granulomata was obtained. One portion of the tissue was snap-frozen in liquid nitrogen for DNA preparation and another portion was processed for histologic evaluation. For histology, the tissue was ®xed in a mixture of 70% ethanol/formalin/glacial acetic acid (20/ 2/1, v/v/v), transferred to 70% ethanol and embedded in a paran block from which four mm thick sections were cut and stained with H&E, Giemsa, PAS, methyl green and pyronine, and Gomori (American Histolabs, Gaithersburg, MD) to con®rm the diagnosis of plasmactytoma.
Genomic DNA and PCR primers
Two methods were employed to prepare high molecular weight genomic DNA: a standard phenol/chloroform extraction protocol that included digestion with proteinase K (100 microg/ml, Boehringer-Mannheim, Indianapolis, IN) and RNAse A (40 microg/ml, Sigma, St. Louis, MO) and the DNA isolation kit, QIAamp tissue (Qiagen, Chatsworth, CA), which was used according to the manufacturer's suggestions. PCR primers were chosen using the primer analysis software Oligo 4.0 (National Biosciences, Plymouth, MN) and prepared by Bioserve Biotechnologies (Laurel, MD). The c-myc primers with the sux`a' were combined with Igh primers with the sux`a' in the ®rst round of PCR, and corresponding c-myc and Igh primer pairs with the sux`b' were combined as nested primer pairs in the second round of two-round, direct PCR ampli®cations. Primer sequences are given in Table 2 .
PCR ampli®cation, cloning and sequencing of junction fragments
Long template and high ®delity PCR methods (Boehringer Mannheim, Indianapolis, IN) were employed that permit, in our experience, detection of Igh/c-myc junctional fragments with an apparent size of up to 10 kbp. PCR hot-start ampli®cations were carried out with 500 ng aliquots of genomic DNA using the following cycling conditions: initial denaturation at 968C for 5 min with the reaction subsequently being held at 808C for the addition of polymerase mix (1.6 units in the ®rst round and 1.2 units in the second round). This was followed by 25 cycles of template denaturation at 958C for 15 s, primer annealing at 628C for 15 s and primer extension at 688C for 4 to 7 min in the ®rst cycle with a progressive prolongation of the extension time by 20 s for each of the subsequent cycles. Final extension times were thus in the order of 11.5 to 14.5 min. For the second round of PCR, 1 ml of reaction mixture from round one was used with nested primer pairs for an additional round of 25 cycles. The concentration of dNTPs (200 mM) and Mg 2+ (1.5 to 1.75 mM ®nal) were the same in both rounds of PCR. PCR products were fractionated by standard agarose gels (BRL, Gaithersburg, MD electrophoresis), stained with ethidium bromide and puri®ed using the QIAquick Gel Extraction Kit (Qiagen, Chatsworth, CA) according to the protocol of the manufacturer. Puri®ed PCR fragments were sequenced using the Femtomole cycle sequencing kit (Promega, Madison, WI) either directly or after cloning into pCRII vector (Invitrogen, San Diego, CA). All recombinational fragments were PCR ampli®ed and sequenced at least twice. Primers designated with sux`a' were used in the ®rst round and primers designated with sux`b' were used in the second round of two round PCR reactions performed with nested primer pairs. 
